Mosaic ImmunoEngineering Inc. (CPMV)
OTC PINK OTC PINK Primary Summary
Mosaic ImmunoEngineering Inc. (CPMV) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Mosaic ImmunoEngineering Inc. ever had a stock split?
Mosaic ImmunoEngineering Inc. Profile
| Biotechnology Industry | Healthcare Sector | Steven W. King CEO | OTC PINK Exchange | 61945M101 CUSIP |
| US Country | 7 Employees | - Last Dividend | 2 Dec 2020 Last Split | - IPO Date |
Overview
Mosaic ImmunoEngineering Inc. is a pioneering entity at the development stage in the biotechnology industry, with its focal mission being to innovate and bring to market a unique immunomodulator platform technology. Spanning across a wide scope, this technology is aimed at combating cancer and infectious diseases, benefiting not just humans but also extending its advantages to veterinary applications. Established in the year 2020, and domiciled in Novato, California, the company stands at the forefront of leveraging viral vector technology for therapeutic gains, particularly emphasizing the cowpea mosaic virus which, notably, poses no infectious risk to either humans or animals.
Products and Services
- MIE-101
The flagship product under development by Mosaic ImmunoEngineering Inc., MIE-101, symbolizes a significant breakthrough in the realm of immunotherapy. Engineered on the foundation of the cowpea mosaic virus, MIE-101 is designed to enlist and enhance the body's immune response against cancer cells and infectious diseases. Its formulation derives from a non-infectious virus in humans and animals, distinguishing it as a novel approach in medical treatments. The strategic development of MIE-101 embodies the company’s commitment to harnessing viral vectors for therapeutic innovations, aiming to provide a potent tool in the fight against some of the most challenging diseases facing both humans and veterinary subjects.
